Question 1

What is COUR Pharmaceuticals developing?

Accepted Answer

COUR Pharmaceuticals is developing first-in-class therapies designed to reprogram the immune system to achieve antigen-specific tolerance for immune-mediated diseases.

Question 2

What is the goal of COUR's platform of immune-modifying nanoparticles?

Accepted Answer

COUR's platform of immune-modifying nanoparticles aims to treat the root cause of immune disease, unlike traditional approaches which only minimize symptoms using toxic immune suppression.

Question 3

What is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease?

Accepted Answer

COUR's lead product for celiac disease, partnered with Takeda, is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease.

Question 4

What has the data from clinical and preclinical settings demonstrated?

Accepted Answer

The data from clinical and preclinical settings demonstrate the opportunity for the COUR nanoparticle platform to address a wide range of immune and inflammatory conditions.

Question 5

What is the focus of COUR's nanoparticle platform?

Accepted Answer

COUR's nanoparticle platform focuses on reprogramming the immune system, inducing tolerance to specific antigen, and preserving immune functionality.

Cour Pharmaceuticals Development

Company Overview

Company Name

Address

Website

Phone

About Cour Pharmaceuticals Development

Frequently Asked Questions about Cour Pharmaceuticals Development

What is COUR Pharmaceuticals developing?

What is the goal of COUR's platform of immune-modifying nanoparticles?

What is the first demonstration of induction of antigen-specific immune tolerance in any autoimmune disease?

What has the data from clinical and preclinical settings demonstrated?

What is the focus of COUR's nanoparticle platform?

Technologies Used

Social Profiles

Key Decision Makers